Curated News
By: NewsRamp Editorial Staff
June 26, 2024
Clene Unveils Long-Term Findings on CNM-Au8 Treatment at ENCALS Meeting
TLDR
- Clene presented new findings on CNM-Au8 treatment's impact on survival rates at the ENCALS meeting, providing a competitive edge for potential investors.
- The presentation showcased long-term survival follow-up data and NfL biomarker results, demonstrating the methodical research process behind the findings.
- CNM-Au8 treatment's positive impact on survival rates and NfL levels offers hope for combating neurodegenerative diseases, making tomorrow better than today for patients.
- Clene's unveiling of long-term findings at the ENCALS meeting provides an insightful look into potential advancements in neurodegenerative disease treatment.
Impact - Why it Matters
This news matters as it reveals significant data on the impact of CNM-Au8 treatment on ALS survival rates and NfL levels, providing hope for those affected by neurodegenerative diseases.
Summary
Clene, a clinical-stage biopharmaceutical company, presented new findings on CNM-Au8 treatment's impact on survival rates and neurofilament light levels from the HEALEY-ALS Platform Trial at the ENCALS meeting in Stockholm, Sweden. The presentation showcased survival follow-up data extending up to 42 months and long-term NfL biomarker results over 76 weeks.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Clene Unveils Long-Term Findings on CNM-Au8 Treatment at ENCALS Meeting
